David G. Maloney
#60,399
Most Influential Person Now
Researcher
David G. Maloney's AcademicInfluence.com Rankings
David G. Maloneycomputer-science Degrees
Computer Science
#3922
World Rank
#4121
Historical Rank
Computational Linguistics
#406
World Rank
#413
Historical Rank
Machine Learning
#833
World Rank
#845
Historical Rank
Artificial Intelligence
#1043
World Rank
#1062
Historical Rank
David G. Maloneyengineering Degrees
Engineering
#3211
World Rank
#4251
Historical Rank
Electrical Engineering
#745
World Rank
#810
Historical Rank
Download Badge
Computer Science Engineering
David G. Maloney's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is David G. Maloney Influential?
(Suggest an Edit or Addition)According to Wikipedia, David G. Maloney is an oncologist and researcher at Fred Hutchinson Cancer Research Center and the University of Washington who specializes in developing targeted immunotherapies for the treatment of blood cancers.
David G. Maloney's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. (2005) (2257)
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. (2016) (1424)
- Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. (2001) (1357)
- IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. (1997) (1245)
- Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. (1982) (847)
- Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. (2017) (809)
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study (2020) (767)
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells (2016) (756)
- Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. (2000) (695)
- Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. (2017) (683)
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. (1997) (645)
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. (1994) (600)
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma (1997) (572)
- Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. (2003) (566)
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. (2016) (541)
- Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. (1998) (541)
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. (2017) (484)
- Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. (2003) (469)
- Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio (2003) (467)
- A clinical trial of anti-idiotype therapy for B cell malignancy. (1985) (461)
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. (2012) (460)
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo (2015) (432)
- Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. (2003) (404)
- Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. (2001) (385)
- Accepted Article Preview : Published ahead of advance online publication (2016) (384)
- New treatment options have changed the survival of patients with follicular lymphoma. (2005) (378)
- Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. (2007) (368)
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. (2003) (364)
- Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. (2004) (335)
- Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience (2017) (327)
- Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. (2004) (326)
- Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. (1997) (326)
- Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. (2014) (324)
- A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. (2000) (315)
- Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. (1999) (300)
- Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. (2007) (297)
- Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. (1998) (288)
- Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. (2006) (286)
- Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. (2017) (283)
- Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. (2008) (283)
- Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. (2004) (270)
- Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. (2005) (265)
- Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. (2011) (260)
- Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. (2003) (259)
- Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. (2008) (259)
- Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. (2004) (257)
- The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. (2010) (254)
- Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. (2002) (251)
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (2011) (248)
- Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis (2006) (245)
- Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. (2002) (242)
- Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation (2008) (238)
- Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. (2005) (236)
- Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. (2004) (232)
- Anti-CD20 antibody therapy for B-cell lymphomas. (2012) (230)
- Rituximab: Mechanism of action and resistance. (2002) (227)
- In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. (1981) (226)
- High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. (2003) (216)
- Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. (2019) (214)
- High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. (2002) (210)
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. (2010) (209)
- Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. (2008) (205)
- Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors (2006) (197)
- Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. (2008) (195)
- IDEC-C 2 B 8 ( Rituximab ) Anti-CD 20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin ’ s Lymphoma (1997) (186)
- Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. (2013) (183)
- Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. (1998) (174)
- Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. (2007) (172)
- The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. (2019) (171)
- Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. (1987) (170)
- Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure. (2020) (168)
- A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. (2003) (162)
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. (2006) (161)
- Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma (1994) (158)
- Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. (2004) (157)
- Rituximab resistance. (2011) (157)
- Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. (1999) (157)
- Late events after treatment with CD19-Targeted Chimeric Antigen Receptor Modified T-cells. (2020) (155)
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. (2010) (154)
- Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance (2018) (150)
- Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. (2020) (149)
- Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. (2018) (148)
- Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. (1986) (144)
- Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. (2008) (144)
- Rituximab: mechanism of action and resistance. (2002) (142)
- Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. (2001) (141)
- Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning (2004) (139)
- Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. (2001) (139)
- Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. (2004) (139)
- Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. (2002) (137)
- Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. (2013) (137)
- CD 20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD 28 and 4-1 BB domains : pilot clinical trial results (2012) (136)
- Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. (2000) (136)
- A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation (2006) (131)
- Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. (1985) (128)
- Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. (2012) (126)
- Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. (1994) (126)
- Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (2014) (126)
- Mechanism of action of rituximab. (2001) (125)
- Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (122)
- Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy (2020) (119)
- High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma. (1996) (118)
- Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. (2006) (115)
- Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. (2001) (114)
- Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade. (2020) (112)
- Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. (2009) (112)
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. (2014) (110)
- High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma. (2007) (109)
- Preclinical and phase I and II trials of rituximab. (1999) (108)
- Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. (2006) (107)
- Immunologic recovery after hematopoietic cell transplantation with nonmyeloablative conditioning. (2003) (106)
- Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation1 (2002) (104)
- Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. (2014) (103)
- Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience (2008) (103)
- Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. (2003) (102)
- 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. (2003) (101)
- High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation (2005) (101)
- Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. (2009) (100)
- Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. (2012) (100)
- Clinical status and optimal use of rituximab for B-cell lymphomas. (1998) (99)
- Non‐myeloablative allografting from human leucocyte antigen‐identical sibling donors for treatment of acute myeloid leukaemia in first complete remission (2003) (98)
- Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. (2005) (97)
- Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia (2011) (97)
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. (2021) (97)
- Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) (2020) (97)
- Increased Incidence of Cytomegalovirus Disease After Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation (1999) (94)
- Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. (2005) (94)
- Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition. (2014) (92)
- Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. (2006) (91)
- Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. (2006) (91)
- Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. (2007) (89)
- Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. (2005) (89)
- Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas (2019) (89)
- Fully Human Bcma Targeted Chimeric Antigen Receptor T Cells Administered in a Defined Composition Demonstrate Potency at Low Doses in Advanced Stage High Risk Multiple Myeloma (2018) (88)
- Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation. (2000) (87)
- Nonmyeloablative Hematopoietic Cell Transplantation (2001) (86)
- Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. (2014) (85)
- Acute renal failure after nonmyeloablative hematopoietic cell transplantation. (2004) (81)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (2018) (79)
- Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas. (1984) (77)
- Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity (2018) (77)
- ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYCOSIS FUNGOIDES AND SEZARY SYNDROME (2014) (76)
- Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (2013) (75)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation. (2009) (73)
- Acquisition of a CD 19-negative myeloid phenotype allows immune escape of MLL-rearranged BALL from CD 19 CART-cell therapy (2016) (72)
- Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products. (2018) (69)
- Allogeneic peripheral blood stem cell graft composition affects early T‐cell chimaerism and later clinical outcomes after non‐myeloablative conditioning (2005) (67)
- Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor-T Cell Therapy. (2019) (67)
- Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. (1996) (67)
- High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort (2017) (67)
- Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. (2001) (66)
- Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. (2011) (65)
- The use of a monoclonal anti-idiotype antibody to study the biology of a human B cell lymphoma. (1981) (64)
- Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone (2012) (63)
- Outcomes of patients with large B‐cell lymphomas and progressive disease following CD19‐specific CAR T‐cell therapy (2019) (62)
- Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies. (2020) (62)
- Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies. (2012) (61)
- Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. (2019) (61)
- Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases). (2004) (61)
- Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation. (2011) (61)
- Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation (2004) (60)
- HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. (2005) (59)
- Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. (2003) (58)
- Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. (2013) (58)
- Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML (2005) (58)
- Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. (1992) (57)
- High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. (2019) (57)
- Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. (2016) (57)
- Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells (1992) (56)
- Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. (2019) (56)
- Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy (2019) (56)
- What is the role for donor natural killer cells after nonmyeloablative conditioning? (2009) (55)
- Non-myeloablative transplantation. (2002) (55)
- Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma (2008) (54)
- NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018. (2018) (54)
- High Rate of Durable Complete Remission in Follicular Lymphoma after CD19 CAR-T cell Immunotherapy. (2019) (54)
- Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes (2015) (53)
- Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (2015) (52)
- Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation. (2009) (51)
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma (2019) (51)
- ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. (2011) (51)
- Unrelated donor status and high donor age independently affect immunologic recovery after nonmyeloablative conditioning. (2006) (51)
- Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. (2014) (51)
- Impact of donor age on outcome after allogeneic hematopoietic cell transplantation. (2015) (51)
- Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs (2011) (50)
- Non-myeloablative hematopoietic stem cell transplantation. (2001) (50)
- Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. (2018) (50)
- Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia (2009) (50)
- Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. (2010) (49)
- The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. (2015) (49)
- Allogeneic hematopoietic cell transplantation for multiple myeloma. (2001) (48)
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial (2022) (48)
- A Prognostic Model Predicting Autologous Transplantation Outcomes in Children, Adolescents and Young Adults with Hodgkin Lymphoma (2015) (47)
- Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T‐cell and natural killer‐cell lymphomas (2010) (46)
- Interim analysis of ZUMA-5: A phase II study of axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL). (2020) (46)
- Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (2013) (45)
- Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia (2015) (44)
- Hodgkin lymphoma, version 2.2015. (2015) (44)
- Biology of Blood and Marrow Transplantation (2015) (44)
- The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation (2010) (43)
- Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. (2005) (42)
- Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. (2001) (42)
- Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. (2006) (42)
- Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation. (2011) (42)
- Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies. (1998) (42)
- Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL (2018) (42)
- Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil (2013) (42)
- Multi‐centre validation of the prognostic value of the haematopoietic cell transplantation‐ specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation (2015) (42)
- Improving the efficacy of reduced intensity allogeneic transplantation for lymphoma using radioimmunotherapy. (2006) (40)
- Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation. (2011) (40)
- Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. (2010) (40)
- Antibody therapy for treatment of multiple myeloma. (1999) (40)
- Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. (2020) (39)
- Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation. (2010) (39)
- Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy. (2019) (39)
- Impact of unrelated donor status on the incidence and outcome of cytomegalovirus infections after non‐myeloablative allogeneic stem cell transplantation (2003) (38)
- Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. (2016) (38)
- Prognostic relevance of ‘early‐onset’ graft‐versus‐host disease following non‐myeloablative haematopoietic cell transplantation (2005) (37)
- A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation (2014) (37)
- Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. (2007) (37)
- Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation (2006) (37)
- Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors. (2007) (37)
- A phase I / II trial of iodine-131 – tositumomab ( anti-CD 20 ) , etoposide , cyclophosphamide , and autologous stem cell transplantation for relapsed B-cell lymphomas (2000) (36)
- ALTERNATIVE DONORS EXTEND TRANSPLANTATION FOR PATIENTS WITH LYMPHOMA WHO LACK AN HLA MATCHED DONOR (2014) (35)
- Nonmyeloablative Hematopoietic Cell Transplantation: Status Quo and Future Perspectives (2002) (34)
- Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. (2015) (34)
- High‐dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma (2008) (33)
- A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab (2013) (33)
- Hodgkin disease/lymphoma. Clinical practice guidelines in oncology. (2006) (33)
- Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow. (1997) (33)
- Rituximab for follicular lymphoma. (2003) (33)
- Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma (2011) (33)
- Engraftment of early erythroid progenitors is not delayed after non‐myeloablative major ABO‐incompatible haematopoietic stem cell transplantation (2002) (32)
- Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy (2021) (32)
- Anti-CD 20 Antibody Therapy for B-Cell Lymphomas (2012) (32)
- Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. (2009) (31)
- Treatment recommendations for patients with Waldenström's Macroglobulinemia (WM) and related disorders: consensus from the Seventh International Workshop on WM (2014) (31)
- High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. (1997) (30)
- Normal T, B, and NK cell counts in healthy donors at 1 year after blood stem cell harvesting. (2000) (29)
- Interleukin-7 improves reconstitution of antiviral CD4 T cells. (2005) (29)
- Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. (2015) (29)
- Long‐term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning (2015) (29)
- Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. (2003) (29)
- Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. (2003) (28)
- Antibody-directed therapies for hematological malignancies. (2002) (28)
- Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects. (2013) (27)
- Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. (2012) (27)
- Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement (2013) (27)
- Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. (2020) (26)
- High Durable CR Rates and Preliminary Safety Profile for JCAR017 in R/R Aggressive B-NHL (TRANSCEND NHL 001 Study): A Defined Composition CD19-Directed CAR T Cell Product with Potential for Outpatient Administration (2018) (26)
- The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. (2011) (26)
- Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape (2016) (26)
- Follicular lymphoma: a model of lymphoid tumor progression in man. (1991) (25)
- Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases (2002) (25)
- Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma: Long-term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0102 Trial. (2019) (25)
- Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (2018) (25)
- A phase 2 trial of CHOP chemotherapy followed by tositumomab / iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma : Southwest Oncology Group Protocol S 9911 (2003) (25)
- Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. (2005) (24)
- Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells. (2016) (24)
- Improved Reconstitution of CD4 T Cells and B Cells But Worsened Reconstitution of Serum IgG Levels After Allogeneic Transplantation of Blood Stem Cells Instead of Marrow (1997) (24)
- High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma (2008) (23)
- Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B‐cell malignancies (2019) (23)
- 131I-Anti-CD45 Antibody Plus Fludarabine, Low-Dose Total Body Irradiation and Peripheral Blood Stem Cell Infusion for Elderly Patients with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). (2005) (22)
- Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. (2007) (22)
- Graft-vs.-Lymphoma Effect in Various Histologies of Non-Hodgkin's Lymphoma (2003) (22)
- Correlation between the numbers of naive T cells infused with blood stem cell allografts and the counts of naive T cells after transplantation. (2003) (22)
- Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab (2016) (22)
- Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma. (2014) (21)
- Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. (2013) (21)
- ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL). (2018) (21)
- Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma (2018) (20)
- Modified total body irradiation as a planned second high-dose therapy with stem cell infusion for patients with bone-based malignancies. (2006) (20)
- Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Relapsed or Refractory Follicular Lymphoma. (2005) (20)
- Therapy of B Cell Malignancies with CD19-Specific Chimeric Antigen Receptor-Modified T Cells of Defined Subset Composition (2014) (20)
- High durable CR rates and preliminary safety profile for JCAR017 in R/R aggressive b-NHL (TRANSCEND NHL 001 Study): A defined composition CD19-directed CAR T-cell product with potential for outpatient administration. (2018) (20)
- Brentuximab vedotin administered to platinum‐refractory, transplant‐naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status (2015) (19)
- Phase I study of immunotherapy for advanced ROR1+ malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells. (2018) (19)
- Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation. (2015) (19)
- Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose (2012) (19)
- in adult B cell ALL patients (2016) (19)
- De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. (2005) (19)
- A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT (2016) (19)
- Agranulocytosis unresponsive to growth factors following rituximab in vivo purging. (2003) (19)
- A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy. (2020) (19)
- Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors. (2004) (18)
- The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation (2007) (18)
- Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL) (2021) (18)
- A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma (2011) (18)
- Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL (2022) (18)
- Lymphoma Regression Induced by Monoclonal Anti-Idiotypic Antibodies Correlates With Their Ability to Induce Ig Signal Transduction and Is Not Prevented by Tumor Expression of High Levels of Bcl-2 Protein (1994) (18)
- Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition. (2015) (17)
- The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma (2007) (17)
- Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. (2011) (17)
- Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. (2016) (17)
- Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. (2017) (17)
- Hodgkin disease/lymphoma. (2008) (16)
- Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-cell Lymphoma. (2019) (16)
- Advances in immunotherapy of hematologic malignancies (1998) (16)
- HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD) (2004) (16)
- Comorbidity, Lactate Dehydrogenase (LDH), and Chemosensitivity Are Independent Predictors of Mortality after Autologous Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Lymphoma. (2007) (16)
- HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD) (2004) (16)
- Kinetics of B, CD4 T, and CD8 T cells infused into humans: estimates of intravascular:extravascular ratios and total body counts. (2002) (15)
- A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL). (2006) (15)
- Comparison of two flow cytometric methods enumerating CD4 T cells and CD8 T cells. (1998) (15)
- Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies (2021) (15)
- Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades (2020) (15)
- A Phase II Trial of 90Y-Ibritumomab Tiuxetan-Based Reduced Intensity Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for Relapsed CD20+ B-Cell Non-Hodgkins Lymphoma (NHL). (2006) (15)
- CD19 CAR-T Cells Are Highly Effective in Ibrutinib-Refractory Chronic Lymphocytic Leukemia (2016) (15)
- Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults 60 Years Old With Relapsed or Refractory B-Cell Lymphoma (2007) (15)
- Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy (2018) (14)
- Fcγ Receptor Polymorphisms Do Not Influence Progression Free Survival (PFS) of Follicular NHL Pateints Treated with Chop Followed by Rituximab (SWOG 9800). (2004) (14)
- Allogeneic transplantation following nonmyeloablative conditioning for aggressive lymphoma (2008) (14)
- Hodgkin lymphoma. (2021) (14)
- Diversity in antibody-based approaches to non-Hodgkin lymphoma (2010) (14)
- Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma (2021) (14)
- Abstract CT131: A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) (2018) (14)
- Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors. (2020) (13)
- Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma (2021) (13)
- Patient Characteristics and Pre-Infusion Biomarkers of Inflammation Correlate with Clinical Outcomes after Treatment with the Defined Composition, CD19-Targeted CAR T Cell Product, JCAR017 (2017) (13)
- Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation. (2008) (13)
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase (2019) (13)
- Nonmyeloablative hematopoietic stem cell transplantation: transplantation for the 21st century. (2001) (13)
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT (2019) (13)
- Cytokine release syndrome (CRS) and neurotoxicity (NT) after CD19-specific chimeric antigen receptor- (CAR-) modified T cells. (2017) (13)
- Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma. (2006) (13)
- Indolent lymphomas: current and emerging treatment approaches. (2006) (12)
- Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). (2020) (12)
- Type of post‐grafting immunosuppression after non‐myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor abo incompatibility (2002) (12)
- Treatment of follicular non-Hodgkin's lymphoma. (2005) (12)
- Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) (2019) (12)
- Retreatment With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma in ZUMA-5 (2020) (12)
- Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century. (2000) (12)
- Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study). (2018) (12)
- Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic leukemia: importance of immunocytochemistry. (1999) (12)
- Safety and preliminary efficacy in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) receiving lisocabtagene maraleucel (Liso-cel) in TRANSCEND NHL 001. (2019) (12)
- CAR-T Cells (2019) (12)
- Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose (2016) (11)
- Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI). (2004) (11)
- High‐dose CD20‐targeted radioimmunotherapy‐based autologous transplantation improves outcomes for persistent mantle cell lymphoma (2015) (11)
- CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY BY BASELINE TUMOR BURDEN IN ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL (2019) (11)
- 90 Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma (2011) (11)
- Second allogeneic hematopoietic cell transplantation for relapse after first allografts (2019) (11)
- Nonmyeloablative hematopoietic stem cell transplantation (2001) (11)
- Antibody therapy has arrived. Now where does it fit? (1999) (11)
- Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) (2021) (11)
- Preliminary Safety Profile of the CD19-Directed Defined Composition CAR T Cell Product JCAR017 in Relapsed/Refractory Aggressive B-NHL Patients: Potential for Outpatient Administration (2017) (11)
- Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms (2019) (11)
- Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates. (2004) (10)
- Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative hlaidentical sibling ALLOGRAFTS (2000) (10)
- Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study (2021) (10)
- Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD 20 Monoclonal Antibody ( IDEC-C 2 BS ) in Patients With Recurrent B-Cell Lymphoma (2000) (10)
- Hematopoietic Cell Transplants (HCT) from HLA-Matched Related (MRD) and Unrelated (URD) Donors for Patients with Hematologic Malignancies Using Low-Dose TBI Conditioning. (2005) (10)
- Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study (2018) (10)
- Low Albumin, High Ferritin, and Thrombocytopenia Before Transplant Predict Non-Relapse Mortality (NRM) Independent of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI). (2009) (10)
- Pre‐transplant comorbidity burden and post‐transplant chronic graft‐versus‐host disease (2015) (10)
- Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone. (2009) (10)
- Prognostic Relevance of “Early-Onset” Graft-Versus-Host Disease Following Nonmyeloablative Hematopoietic Cell Transplantation. (2004) (10)
- Anti-CD19 CAR T cell therapy for lymphoma — off to the races! (2019) (10)
- Late Effects of CD19-Targeted CAR-T Cell Therapy (2018) (10)
- An Update of a Phase II Trial of CHOP Followed by Tositumomab/Iodine I-131 Tositumomab (Bexxar®) for Front-Line Treatment of Advanced Stage, Follicular Lymphoma: Southwest Oncology Group Protocol 9911. (2005) (10)
- Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy (2011) (9)
- Low T cell receptor excision circle levels in patients thymectomized 25-54 years ago. (2003) (9)
- Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience (2019) (9)
- Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. (2020) (9)
- Incidence of herpesvirus infections following nonmyeloablative allogeneic stem cell transplantation (2000) (9)
- A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma. (2005) (9)
- CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas (2019) (9)
- Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) (2020) (9)
- Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL (2019) (9)
- Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma (2011) (9)
- Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL (2019) (9)
- Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL). (2007) (9)
- Autologous (auto) Versus Allogeneic (allo) Hematopoietic Cell Transplantation (HCT) for T-NHL: A CIBMTR Analysis (2010) (9)
- New Treatment Options Have Changed the Natural History of Follicular Lymphoma. (2004) (9)
- Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. (2008) (9)
- Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma. (2018) (8)
- Monoclonal Antibodies to Human Lymphocytes (1984) (8)
- Radioimmunotherapy consolidation using 131I-tositumomab for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in first remission (2016) (8)
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom’s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect. (2006) (8)
- Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24). (2021) (8)
- Immunotherapy in lymphoma (2017) (8)
- Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy (2017) (8)
- Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). (2008) (7)
- Myeloablative Versus Nonmyeloablative Hemopoietic Cell Transplantation (HCT) for Patients with Myelodysplasia (MDS) or AML with Multilineage Dysplasia Following MDS (tAML). (2004) (7)
- Indications for Hematopoietic Stem Cell Transplantation in Patients with Waldenstrom's Macroglobulinemia: A Consensus Project of the EBMT Lymphoma Working Party (LWP)/ European Consortium for Waldenstrom's Macroglobulinemia (ECWM)/International Waldenstrom's Macroglobulinemia Foundation (IWMF) (2017) (7)
- Advances in the immunotherapy of hematologic malignancies: cellular and humoral approaches. (1999) (7)
- Assessing donor chimerism level among CD3 T, CD4 T, CD8 T, and NK cells predicts subsequent graft rejection, GVHD, and relapse after allogeneic HCT with nonmyeloablative conditioning (2005) (7)
- What is the role of maintenance rituximab in follicular NHL? (2008) (7)
- Impact of Lisocabtagene Maraleucel (liso-cel) Treatment on Health-Related Quality of Life and Health Utility in Patients (pts) with Relapsed/Refractory (R/R) Aggressive B Cell Non-Hodgkin Lymphoma (NHL): Transcend NHL 001 (2019) (7)
- A Modified Hematopoietic Cell Transplantation (HCT)-Specific-Comorbidity Index. (2004) (7)
- Immunoglobulin Free Light Chain (FLC) and Heavy Chain/Light Chain (HLC) Assays – Comparison with Electrophoretic Responses in Multiple Myeloma (MM) (2011) (7)
- Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma (2020) (7)
- Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review (2010) (6)
- Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. (2021) (6)
- Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. (2018) (6)
- Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma (2018) (6)
- Susceptibility of commonly used ferritin assays to the classic hook effect (2016) (6)
- A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A M (2009) (6)
- Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity (2015) (6)
- Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells (2019) (6)
- Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years. (2008) (6)
- Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT). (2005) (6)
- The Mantle Cell Lymphoma International Prognostic Index (MIPI) at Diagnosis Is Associated with Survival of Mantle Cell Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. (2008) (6)
- Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. (2020) (6)
- Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial (2016) (6)
- Treatment of patients (pts) with chemotherapy-refractory chronic lymphocytic leukemia (CLL) with nonmyeloablative (NM) conditioning and hematopoietic cell transplantation (HCT) from HLA-matched related (MRD) or unrelated donors (URD) (2004) (6)
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia (2008) (5)
- A Phase I/II Study Of Fludarabine, Cyclophosphamide, Rituximab and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy In Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Leukemia (SLL) (2013) (5)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy (2021) (5)
- Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (5)
- Validation of the predictive power of the hematopoietic cell transplantation-comorbidity index (HCT-CI) for non-relapse mortality (NRM) and survival after allogeneic HCT (2006) (5)
- Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. (2018) (5)
- The thymus is typically small at 1 year after autologous or allogeneic T-cell-replete hematopoietic cell transplantation into adults (2004) (5)
- What is the role for donor NK cells after nonmyeloablative conditioning (2007) (5)
- Allogeneic hematopoietic cell transplant for patients with end stage renal disease requiring dialysis – a single institution experience (2017) (5)
- Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel (2022) (5)
- TRANSCEND: Lisocabtagene Maraleucel (liso-cel; JCAR017) Healthcare Resource Utilization in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (2018) (5)
- Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells. (2018) (4)
- Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study (2018) (4)
- High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics (2020) (4)
- HLA-Matched Related (MRD) or Unrelated Donor (URD) Non-Myeloablative Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Refractory and Relapsed Aggressive Non Hodgkin Lymphoma (NHL). (2004) (4)
- Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes (2011) (4)
- TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017). (2019) (4)
- Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. (2019) (4)
- Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study (2017) (4)
- Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icans after CAR T-Cell Therapy (2021) (4)
- A Phase I Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy with Escalating Doses of Fludarabine Followed by Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥ 60 Years of Age with High-Risk or Relapsed/Refractory B-Cell Lymphoma (2011) (4)
- Continued Excellent Outcomes in Previously Untreated Follicular Lymphoma Patients after Treatment with CHOP Plus Rituximab or CHOP Plus (131) Iodine-Tositumomab - Long Term Follow-up of Phase III Randomized Study SWOG S0016 (2016) (4)
- Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B-cell Malignancies. (2020) (4)
- Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. (2020) (4)
- Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts (2014) (4)
- The Impact Of Donor Type And ABO Incompatibility On Transfusion Requirements After Nonmyeloablative Hematopoietic Cell Transplantation (HCT) (2010) (4)
- Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases. (2005) (4)
- Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL (2021) (4)
- Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma (2014) (4)
- Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy (2021) (4)
- Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) (2010) (4)
- SWOG S0410/BMT CTN 0703: A Phase II Trial of Tandem Autologous Stem Cell Transplantation (AHCT) for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma (HL) (ClinicalTrials.gov Identifier: NCT00233987) (2014) (4)
- The Follicular Lymphoma International Prognostic Index (FLIPI) as Part of a Proposed Prognostic Model for Follicular Lymphoma Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation (ASCT). (2004) (3)
- Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5. (2021) (3)
- Humoral and Cellular Responses to SARS-CoV-2 Vaccines Before and After Chimeric Antigen Receptor-Modified T Cell Therapy (2022) (3)
- Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma (1995) (3)
- Prophylactic Natural Killer Cell Immunotherapy Following HLA-Haploidentical Hematopoietic Cell Transplantation Prevents Relapse and Improves Survival in Patients with High-Risk Hematological Malignancies (2016) (3)
- Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes (2019) (3)
- Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma (2022) (3)
- Naïve CD4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ ROR1-CAR T Cells (2011) (3)
- Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL). (2006) (3)
- Safety and Efficacy of Escalating Doses of 90 Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma (2018) (3)
- The Role of Hematopoietic Cell Transplantation (HCT) for Burkitt Lymphoma: a Report From the Center for International Blood and Marrow Transplant Research (CIBMTR) (2010) (3)
- Non-Hodgkin's lymphoma (1995) (3)
- Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (2013) (3)
- Patient-Reported Outcomes at Time of CAR-T Cell Therapy (2020) (3)
- Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (2020) (3)
- Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation (2013) (3)
- Factors Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy (2020) (3)
- Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Poor Risk, Relapsed or Refractory Multiple Myeloma. (2004) (3)
- Phase I/II multisite trial of optimally dosed clofarabine and low‐dose TBI for hematopoietic cell transplantation in acute myeloid leukemia (2019) (3)
- In‐vivo purging of the circulating clonal T‐cells with Alemtuzumab prior to autologous peripheral blood hematopoietic cell mobilization and transplantation (2011) (3)
- 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution (2014) (3)
- Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). (2007) (3)
- Not so crystal clear: observations from a case of crystalline arthritis with cytokine release syndrome (CRS) after chimeric antigen receptor (CAR)-T cell therapy (2018) (3)
- Normal anti-CD3-stimulated proliferation of CD4 T cells at one year after allogeneic marrow transplantation. (1999) (3)
- Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) (2020) (3)
- Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*). (2021) (3)
- Nonmyeloablative and Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies: Outcomes with HLA-Matched Unrelated Donors Compared to HLA-Identical Sibling Donors. (2005) (3)
- Tandem Autologous and Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-matched Related Or Unrelated Donors for Advanced Lymphoma Or Chronic Lymphocytic Leukemia (CLL) (2009) (3)
- Efficacy of High-Dose Therapy and Autologous Stem Cell Transplantation for Chemoresistant Hodgkin’s Lymphoma. (2005) (3)
- Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). (2007) (2)
- Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (2018) (2)
- Assessing readmission after axicabtagene ciloleucel immunotherapy. (2020) (2)
- A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL) (2011) (2)
- Rituximab and Interleukin 2 (IL2) as treatment for CD20+ non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT). (2004) (2)
- The Joint Role of Comorbidity and Performance Status (PS) in Predicting Morbidity after Allogeneic Nonmyeloablative Hematopoietic Cell Transplantation (HCT). (2006) (2)
- Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenström macroglobulinemia: evidence for a graft-versus-lymphoma effect (2018) (2)
- Outcomes among Patients with Recurrent High-Risk Hematologic Malignancy after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Cell Transplantation. (2006) (2)
- Fludarabine, Cyclophosphamide, Rituximab (FCR) and Vorinostat Followed By Rituximab and Vorinostat Maintenance Therapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) - Final Results of a Phase I/II Study (2016) (2)
- Poor Outcomes Among Patients Failing Dose-Adjusted EPOCH in Aggressive Lymphoma: A Collaborative, Retrospective Study (2015) (2)
- Brentuximab Vedotin Administered To Platinum-Refractory Transplant Naïve Hodgkin Lymphoma Patients Can Increase The Proportion Achieving FDG-PET Negative Status (2013) (2)
- MONOCLONAL ANTI-IDIOTYPE ANTIBODY THERAPY OF B-CELL LYMPHOMA: LYMPHOMA REGRESSION CORRELATES WITH THE ABILITY OF THE ANTIBODY TO INDUCE IMMUNOGLOBULIN SIGNAL TRANSDUCTION IN VITRO AND IS NOT PREVENTED BY TUMOR EXPRESSION OF HIGH LEVELS OF BCL-2 PROTEIN (1993) (2)
- Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond. (2021) (2)
- Experience of Prior Anti-CD19 Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Non-Hodgkin Lymphoma (B-NHL) Receiving Lisocabtagene Maraleucel (liso-cel), an Investigational Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Product (2021) (2)
- Alternative Donor Transplantation For Adults With Lymphoma: Comparison Of Umbilical Cord Blood Versus 8/8 HLA-Matched Donor (URD) Versus 7/8 URD (2013) (2)
- Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intentsity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis (2013) (2)
- Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter? (2017) (2)
- Reduced Intensity Conditioning with Allogeneic Hematopoietic Cell Transplantation for the Treatment of High-Risk Acute Lymphoblastic Leukemia. (2009) (2)
- Higher Doses of Transplanted CD34+, CD3+ and CD8+ Cells Are Associated with Better Donor T-Cell Chimerism and Less Graft Rejection, but Not with GVHD after Nonmyeloablative Conditioning for Unrelated Hematopoietic Cell Transplantation. (2004) (2)
- HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY (2019) (2)
- MUM1 Expression in Follicular Lymphoma Is a Poor Prognostic Marker in Patients Treated with Immunochemotherapy (SWOG 9800/9911) but Not Chemotherapy Alone (SWOG 8809): A Southwest Oncology Group Correlative Science Study (2008) (2)
- A phase III randomized intergroup trial (S0016) comparing CHOP plus rituximab with CHOP plus iodine-131-tositumomab for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. (2012) (2)
- Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation (2015) (2)
- Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma. (2005) (2)
- CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL. (2021) (2)
- Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy (2019) (2)
- Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes (2011) (2)
- The immunobiology of B-cell lymphoma. Studies with anti-idiotype antibodies (1985) (2)
- Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma (2018) (2)
- Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts (2012) (2)
- Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM). (2007) (2)
- IDEC-C2B8: INITIAL PHASE II RESULTS IN PATIENTS WITH B-CELL LYMPHOMA (1994) (2)
- Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT (2020) (2)
- Conditioning Intensity in Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Diffuse Large B-Cell Lymphoma (DLBCL) (2011) (2)
- Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM). (2007) (2)
- Outcomes of Early Relapse Following Non-Myeloablative Allogeneic Transplant for Lymphoma. (2009) (2)
- Prognostic Factors On Outcome of Mantle Cell Lymphoma Patients Relapsing After Autologous Hematopoietic Stem Cell Transplantation. (2009) (2)
- The Impact of Histologic Grade on the Outcome of High-Dose Therapy and Autologous Stem Cell Transplantation for Follicular Lymphoma. (2005) (2)
- Comorbidity, History of Alcohol Disorders, and LDH Predict Non-Relapse Mortality (NRM) Among Recipients of Autologous Hematopoietic Cell Transplantation (HCT) for Lymphoma (2014) (2)
- Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML. (2004) (2)
- Monoclonal Antibodies in the Treatment of Human Leukemias and Lymphomas: Applications of Flow Cytometry (1984) (2)
- Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma (2020) (2)
- Prediction of Progression-Free Survival with Brentuximab Vedotin Therapy for Relapsed Hodgkin Lymphoma: A Retrospective Analysis (2014) (2)
- Randomized Comparison of Melphalan 200 Mg/m2 v. 280 Mg/m2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation (2012) (2)
- Hodgkin Lymphoma Version 1 . 2017 Clinical Practice Guidelines in Oncology (2017) (2)
- Phase I Trial Results Testing Adoptively Transferred T Cells Expressing CD20-Specific Chimeric Antigen Receptors Containing CD28 and CD137 Costimulatory Domains In Patients with Mantle Cell Lymphoma and Indolent Lymphoma (2010) (2)
- Nonmyeloablative conditioning for stem cell allografts with low-dose tbi (2000) (1)
- Tandem transplant with autografting followed by non-myeloablative allografting for treatment of multiple myeloma: an Italian multi center trial (2003) (1)
- High Efficacy and Low Toxicity of MB-106, a Third Generation CD20 Targeted CAR-T for Treatment of Relapsed/Refractory B-NHL and CLL (2022) (1)
- Immunologic Recovery after Nonmyeloablative (NM) Conditioning: A Comparison between Related Versus Unrelated Donor Hematopoietic Cell Transplantation (HCT). (2005) (1)
- recurrent B-cell lymphoma anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with Phase I clinical trial using escalating single-dose infusion of chimeric (2011) (1)
- Low Achievement of End of Life Quality Measures in Large B-Cell Lymphoma Patients Who Progressed after CD19-Specific CAR-T Cell Therapy (2019) (1)
- A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables. (2010) (1)
- Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning after Failed Myeloablative HCT: Factors Affecting Outcomes. (2005) (1)
- transplant conditioning for patients with persistent high-risk B-cell lymphoma (2016) (1)
- Feasibility and Toxicity of Nonmyeloablative Hematopoietic Cell Transplantation (HCT) with or without Imatinib for Philadelphia Chromosome (Ph+) Acute Lymphoblastic Leukemia (ALL). (2004) (1)
- Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen. (2007) (1)
- Immunotherapy With Rituximab (RITUXAN)/Interleukin 2 (IL-2) Following Autologous Peripheral Blood Stem Cell Transplant (ASCT) as Treatment for CD20 Positive Non-Hodgkin's Lymphoma (2006) (1)
- Platelet and Red Blood Cell (RBC) Transfusion Requirements of Nonmyeloablative (NM) HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation (HCT): Influence of Genetic Disparity and ABO-Incompatibility. (2006) (1)
- 368: Longer follow up of patients (pts) with advanced chronic lymphocytic leukemia (CLL) treated with nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) (2007) (1)
- Maintaining life in indolent lymphoma from evidence-based medicine to clinical practicel (2009) (1)
- Hematopoietic Bone Marrow Transplantation (BMT) for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using HLA-Haploidentical Related Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Befor (2012) (1)
- Generation of T-cells reactive against CT-7 and BCMA peptides: Potential targets for T-cell immunotherapy of multiple myeloma. (2006) (1)
- Positive Pre-Allogeneic Hematopoietic Cell Transplantation (alloHCT) PET Scan in Patients with Non-Hodgkin Lymphoma (NHL) Predicts Higher Risk of Relapse but Has No Impact on Survival (2015) (1)
- macroglobulinemia (WM) and related disorders: IWWM-7 consensus Treatment recommendations for patients with Waldenström (2014) (1)
- Another piece of the puzzle (2002) (1)
- Stem cell transplantation (2012) (1)
- FCgamma Receptor Polymorphisms Do Not Influence the Outcome of Treatment with Rituximab Followed by Active Immunotherapy with Mitumprotimut-T (FavId®, Id-KLH). (2007) (1)
- Impact of Pre-Transplant Comorbidities on the Rate of- and Mortality-Following Acute Graft-Versus-Host Disease (GVHD) After Allogeneic Hematopoietic Cell Transplantation (HCT) (2011) (1)
- Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in Patients with End Stage Renal Disease Requiring Dialysis – a Single Institution Experience (2014) (1)
- Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (2019) (1)
- Outcomes after Autologous Stem Cell Transplantation for Mantle Cell Lymphoma Based on Remission Status and Induction Chemotherapy Regimen. (2007) (1)
- Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells (2021) (1)
- Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC+ B-Cell Lymphoma (2014) (1)
- Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival (2018) (1)
- 56 Changing patterns in the risk for Cytomegalovirus infection and disease and treatment-related outcomes in the Era of preemptive antiviral therapy (2006) (1)
- Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product (2020) (1)
- Falling Serum Albumin Predicts Severity of Acute Graft-Vs.-Host Disease and Non-Relapse Mortality After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation. (2009) (1)
- Repeat Infusions of CD19 CAR-T Cells: Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival (2020) (1)
- Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL) (2010) (1)
- Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL). (2007) (1)
- Donor NK Cell Engraftment and Overall and Progression-Free Survivals after Allogeneic Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning. (2005) (1)
- Nonmyeloablative hematopoietic cell transplantation (HCT) for treatment of patients (pts) with fludarabine-refractory chronic lymphocytic leukemia (CLL) results in prolonged median survival. (2006) (1)
- Reply to “Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story?” Haematologica. 2012;97(11):e45 (2012) (1)
- Platelet and Red Blood Cell (RBC) Transfusion Requirements of Nonmyeloablative (NM) HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation (HCT): Influence of Genetic Disparity and ABO-Incompatibility. (2006) (1)
- TID compared to BID mycophenolate mofetil (MMF) improves donor chimerism and engraftment rates without increasing postgrafting toxicities after unrelated peripheral blood stem cell (PBSC) transplantation (HCT) with nonmyeloablative conditioning (2004) (1)
- Workshop on Waldenström's Macroglobulinemia Update on treatment recommendations from the Third International (2008) (1)
- Multivariate Analyses Indicate That the Cytokine Response to Lymphodepletion May be Better Associated Than Lymphodepletion Intensity with the Efficacy of CD19 CAR-T Cell Immunotherapy for Aggressive B-Cell Non-Hodgkin Lymphoma (2019) (1)
- Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) (2021) (1)
- 5.53 The Anti-Tumor Reactivity of ROR1-CAR Modified T Cells Depends on the Targeted Epitope, CAR-Affinity and Design of the CAR Extracellular Domain (2011) (1)
- Effect of Graft Source and Transplant Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Mantle Cell Lymphoma (MCL): A Cibmtr Analysis (2012) (1)
- Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning (2015) (1)
- Impact of Conditioning Regimen Intensity On the Outcomes of Allogeneic Hematopoietic Cell Transplantation for Refractory Grade-III Follicular (FL-III) and Diffuse Large B-Cell Lymphomas (DLBCL): A Cibmtr Analysis (2012) (1)
- A Prospective Phase II Study on Tandem Autografting-Nonmyeloablative Allografting for Newly Diagnosed Myeloma: Final Results of the Gruppo Italiano Trapianto Midollo Osseo. (2007) (1)
- Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2BS) in Patients With Recurrent B-Cell Lymphoma (2000) (1)
- IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL) (2020) (1)
- Anti-HLA antibodies in recipients of CD19 versus BCMA-targeted CAR T-cell therapy. (2022) (1)
- Review of single agent IDEC-C2B8 safety and efficacy results in low-grade or follicular non-Hodgkin's lymphoma (NHL) (1997) (0)
- Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). (2020) (0)
- Durable responses after CD19‐targeted CAR‐T cell immunotherapy with concurrent ibrutinib for CLL after prior ibrutinib failure (2019) (0)
- Building and Sailing the Ship Simultaneously: A Programmatic Ecosystem for Cellular Based Therapies (2020) (0)
- bone marrow transplantation Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic (2011) (0)
- Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed To Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning. (2006) (0)
- Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma (2021) (0)
- Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma (2004) (0)
- Tandem autografting-nonmyeloablative allografting for newly diagnosed multiple myeloma: The GITMO (gruppo italiano trapianto midollo osseo) experience (2007) (0)
- 229 A2B530, an autologous CEA-directed Tmod T-cell therapy with an inhibitory receptor gated by HLA-A*02 to target colorectal, pancreatic, and lung cancer (2022) (0)
- Abstract CT215: LB1901: A phase 1, open-label, multicenter, multicohort study of CD4-targeted chimeric antigen receptor T cells (CD4-CAR-T) in relapsed or refractory T-cell lymphoma (TCL) (2022) (0)
- Allogeneic Transplant with Standard Conditioning, Reduced Intensity, or Non-Myeloablative Conditioning Regimen for Multiple Myeloma (MM). (2005) (0)
- Predicted Fludarabine Exposure Is Independently Associated with CRS and ICANS after CD19 CAR T-Cell Therapy (2022) (0)
- Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma (2022) (0)
- HLA-Matched Unrelated Donor HCT after Nonmyeloablative Conditioning for Patients with Chronic Myeloid Leukemia. (2004) (0)
- Impact of Lab Abnormalities at the Time of Progression in Patients Receiving CD19-Specific CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphomas (2019) (0)
- CD8+ T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor Specifically Recognize ROR1 Positive B Cell Tumors. (2009) (0)
- Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial. (2016) (0)
- OP61 Stem cell allotransplantation for NHL (2007) (0)
- LA-Matched Unrelated Donor Hematopoietic Cell ransplantation after Nonmyeloablative Conditioning or Patients with Chronic Myeloid Leukemia (2005) (0)
- Chapter 80. Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma (2007) (0)
- Low-Dose Total Body Irradiation (TBI) and Fludarabine Conditioning for Hematopoietic Cell Transplantation (HCT) in Patients with HLA-Class I Mismatched Donors. (2007) (0)
- Ex Vivo Immunophenotyping of Adoptively Transferred T Cells Using the SP6800 Spectral Analyzer (2016) (0)
- A Phase II Study of Xcellerated T Cells™ in Patients with Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma (NHL). (2004) (0)
- CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma Using a Fully Human CD19-Targeted Single Chain Variable Fragment: Results of a First-in-Human Phase I/II Study (2022) (0)
- Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant (2013) (0)
- Y-90-Ibritumomab Tiuxetan, Fluadarabine and TBI Based Non-Myeloablative Allogeneic Transplant Conditioning for High-Risk B-Cell Lymphoma (2010) (0)
- Fully Human CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma: Results of a First-in-Human Phase I/II Study (2023) (0)
- Comparison of Lung Function after Nonmyeloablative Versus Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation. (2004) (0)
- Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy (2022) (0)
- Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation for the Treatment of Patients with Poor-Risk, Relapsed or Refractory Multiple Myeloma (2007) (0)
- Clinical Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients with Richter's Transformation (RT) to Aggressive Non-Hodgkin Lymphoma (aNHL): a Single-Institution Experience (2017) (0)
- Maintenance Therapy With Low Dose Thalidomide, Dexamethasone, and Clarithromycin (BIAXIN) (BLT-D) Following Autologous Transplant (ASCT) for Multiple Myeloma (MM) (2011) (0)
- monoclonal antibody Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 (2011) (0)
- IDEC-C2B8-induced B cell depletion is not associated with significant immune suppression or infection (1997) (0)
- 170: Long-Term Outcome of Nonmyeloalative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM) (2008) (0)
- 19. Unexpected karyotype findings and lineage switching during anti-CD19 CAR-T immunotherapy for lymphoid malignancies (2019) (0)
- Reduced-intensity allografting as first transplantation approach in relapsed/refractory grade 1-2 follicular lymphoma provides improved outcomes in long-term survivors Biol Blood Marrow Transplant (2015) (0)
- Effect of Prior Rituximab on Residence Time of I131 Tositumomab Consolidation Therapy in Patients (pts) with Non Hodgkin’s Lymphoma (NHL): Analysis of SWOG Clinical Trials. (2008) (0)
- Abstract CT232: Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*) (2020) (0)
- Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors (2010) (0)
- BEAM vs BuMelTT high-dose chemotherapy (HDC) followed by autologous hematopoietic stem cell infusion (HSCT) in the treatment of non-Hodgkin’s lymphoma (2005) (0)
- Impact of Peri-Transplant Rituximab and Host/Donor Fc Receptor Polymorphisms for Patients with Relapsed or Refractory CD20+ B-Cell Malignancies (2020) (0)
- Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI). (2007) (0)
- Hematopoietic cell transplantation (HCT)-specinc comorbidity index : a new tool for risk assessment before allogeneic HCT. Commentary (2005) (0)
- A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience (2015) (0)
- Abstract OT-13-07: Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*) (2021) (0)
- Recovery from and consequences of severe iatrogenic lymphopenia (induced to treat autoimmune diseases) (2005) (0)
- A Phase Ib Open-Label Study Evaluating the Safety and Efficacy of NKTR-255 in Combination with CD19-Directed CAR-T Cell Therapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) (2022) (0)
- A PILOT TRIAL OF ADRIAMYCIN, PEMBROLIZUMAB, VINBLASTINE AND DACARBAZINE (APVD) FOR PATIENTS WITH UNTREATED CLASSICAL HODGKIN LYMPHOMA (2019) (0)
- 131I-Tositumomab Consolidation Radioimmunotherapy (RIT) In Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Or Small Lymphocytic Lymphoma (SLL) In First Remission (2013) (0)
- Unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with poor risk, relapsed or refractory multiple myeloma (2004) (0)
- Preservation of CD20-Specific Chimeric Antigen Receptor T Cell Function in the Presence of Residual Rituximab (2015) (0)
- Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN) (2017) (0)
- autografts for the treatment of patients with multiple myeloma Allografting with nonmyeloablative conditioning following cytoreductive (2013) (0)
- Axicabtagene Ciloleucel (Axi-Cel) versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: ZUMA-7, A Phase 3, Randomized Study (2018) (0)
- CMV Infection and Disease after Nonmyeloablative (NM) HCT Revisited: Incidence, Risk Factors, Ganciclovir-Related Neutropenia and Outcome. (2005) (0)
- IL-15 Serum Concentrations and CD19 CAR T-Cell Therapy: Impact on Clinical Outcomes and In Vivo CAR T Cell Kinetics (2021) (0)
- Clinical Outcomes of CLL Patients with Relapsed or Refractory Disease after CD19-Specific CAR-T Therapy (2020) (0)
- A Large Cohort Analysis of CMV Viral Load and Ganciclovir-Related Neutropenia in Nonmyeloablative (NM-HCT) and Myeloablative (M-HCT) Allogeneic Hematopoietic Cell Transplant Recipients. (2007) (0)
- Biologic Assignment Clinical Trials in Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Myeloma: Baseline Characteristics by Treatment Allocation from BMT CTN 0102 According to Availability of an HLA-Matched Sibling Donor. (2007) (0)
- Efficacy of Nonmyeloablative Hematopoietic Cell Transplant (HCT) in Secondary Myelodysplastic Syndrome (MDS) and Its Impact on the Primary Disease. (2005) (0)
- A Phase II Trial Combining Radiolabeled Anti-CD45 Antibody with Fludarabine and Low-Dose Total Body Irradiation (TBI) Followed by Related or Unrelated Hematopoietic Cell Transplantation for Patients Under Age 50 with Advanced Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (2012) (0)
- Non-Responsiveness to Immediate Pre CAR-T Treatment Does Not Preclude Response to Axicabtagene Ciloleucel in Relapsed and Refractory Aggressive B Cell Lymphomas (2021) (0)
- Long-term Follow-up of CD20-directed Chimeric Antigen Receptor Adoptive T-cell Therapy (2022) (0)
- PCN90 ASSESSMENT OF UTILITIES FOR ADVERSE EVENTS (AES) ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA (LBCL) (2020) (0)
- Use of Gene-Modified T-Cells as Antigen Presenting Cells (T-APC) for Vaccination Against Myeloma Antigens. (2007) (0)
- onmyeloablative Unrelated Donor Hematopoietic Cell ransplantation to Treat Patients with Poor-Risk , elapsed , or Refractory Multiple Myeloma (2007) (0)
- variant cells antitumor effect nor prevent the emergence of idiotype-negative the addition of a short course of chemotherapy does not interfere with Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the (2011) (0)
- Factors Leading to Rituximab Resistance and How to Overcome Them (2009) (0)
- ONE-HUNDRED-EIGHT CONSECUTIVE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THE TANDEM AUTO-TBI BASED MINI-ALLO APPROCH (2006) (0)
- 196. Antibodies to Vaccine-preventable Infections After CAR-T Cell Immunotherapy for B Cell Malignancies (2020) (0)
- Anakinra for refractory CRS or ICANS after CAR T-cell therapy. (2023) (0)
- 491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy (2021) (0)
- AUTOGRAFTING FOLLOWED BY LOW DOSE TBI BASED NON MYELOABLATIVE ALLOGRAFTING IN MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2003) (0)
- Impacts of Comorbidities on Outcomes of Patients (pts) Diagnosed with B-Cell Malignancies and Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative (NM) vs Myeloablative (M) Conditioning. (2006) (0)
- Association of reduced intensity conditioning (RIC) allograft (alloHCT) as first transplant approach in relapsed/refractory grade 3(G-3) follicular lymphoma (FL) with improved outcomes in long-term survivors. (2015) (0)
- Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion (2016) (0)
- 643 Autopsy review of chimeric-antigen receptor T cell therapy: a single institution experience (2020) (0)
- transplantation Factors affecting antibody levels after allogeneic hematopoietic cell (2011) (0)
- Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study (2022) (0)
- results antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial CD20-specific adoptive immunotherapy for lymphoma using a chimeric (2012) (0)
- 639 BASECAMP-1: Leveraging HLA loss of heterozygosity in solid tumors by NGS to identify patients with relapsed solid tumors for future CEA and MSLN logic-gated Tmod™ CAR T-cell therapy (2022) (0)
- TANDEM AUTOGRAFTING-NONMYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: THE GITMO EXPERIENCE (2007) (0)
- Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Total Body Irradiation (3 or 4 Gy) after Failure of First Allografts. (2008) (0)
- Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product (2021) (0)
- Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5 (2021) (0)
- 12‐LOX Modulates FcγRIIa‐mediated Platelet Response (2015) (0)
- AUTOGRAFTING FOLLOWED BY NON MYELOABLATIVE TBI-BASED ALLOGRATING FOR TREATMENT OF MULTIPLE MYELOMA: A MULTI-CENTER TRIAL (2002) (0)
- Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma (2015) (0)
- Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response. (2006) (0)
- Prospective BASECAMP-1 experience in patients with gastrointestinal (GI) cancer: Identifying patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for a future therapeutic trial exploiting LOH as a tumor vulnerability. (2023) (0)
- Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL) (2022) (0)
- Conditioning Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Kinetics of Engraftment in Patients with Hematological Malignancies Given (2009) (0)
- Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. (2021) (0)
- Strategy to Obtain Monoclonal Anti-Idiotype Antibodies (1983) (0)
- Mono clonal anti idiotype reagents for the study of a b cell tumor (1981) (0)
- Clinical Outcomes of Hematopoietic Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma Transformed From Follicular Lymphoma (2013) (0)
- The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologus Stem Cell Transplant for Mantle Cell Lymphoma (2011) (0)
- Cellular Immunotherapies for Leukemia Patients (2017) (0)
- EARLY RESULTS OF A PHASE II STUDY ADDING PERI-TRANSPLANT RITUXIMAB TO NONMYELOABLATIVE CONDITIONING AND ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR PATIENTS (PTS) WITH HIGH-RISK FLUDARABINE-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (2012) (0)
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results (2012) (0)
- Risk Factors Predicting Outcomes of Autologous Hematopoietic Cell Transplantation (autoHCT) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (HL): A CIBMTR Analysis (2015) (0)
- Primary Treatment Classical Hodgkin Lymphoma : Lymphocyte-predominant Hodgkin Lymphoma : NCCN Hodgkin Disease / Lymphoma Panel Members Summary of Guidelines Updates (2001) (0)
- Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial (2019) (0)
- Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation (2009) (0)
- Pretransplant Minimal Residual Disease (MRD) Positivity Independently Predicts Survival in a Unselected Cohort of Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission (2015) (0)
- Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial (2019) (0)
- Radioimmunotherapy-Augmented Nonmyeloablative Allogeneic Transplantation Improves Outcomes for Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Results of an Adjusted Cohort Analysis (2014) (0)
- PF305 ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROTOXICITY BY AGE AND LYMPHODEPLETING CHEMOTHERAPY USE IN ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL (2019) (0)
- Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma (2014) (0)
- TANDEM AUTO-MINI ALLO APPROACH FOR NEWLY DIAGONSED MULTIPLE MYELOMA: AN UPDATE OF THE ITALIAN EXPERIENCE (2005) (0)
- Rituximab A nti-CD20 M onoclonal A ntibody T herapy i n Non-Hodgkin's L ymphoma: S afety a nd E fficacy o f Re-Treatment (2000) (0)
- Phase I Trial of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder for Adults with Relapsed/Refractory B-ALL (2023) (0)
- Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients. (2008) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation with a Nonmyeloablative Conditioning Regimen (2003) (0)
- and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation (2005) (0)
- transplantation in monkeys Interleukin-7 improves CD4 T cell reconstitution after autologous CD34 cell (2013) (0)
- Effect of Rituximab On the Activity of T Cells Expressing CD20-Specific Chimeric Antigen Receptors (2012) (0)
- 275: Impacts of comorbidities on outcomes of patients (pts) younger than 60 years old, diagnosed with indolent malignancies and treated with allogeneic hematopoietic cell transplantation (HCT): A model for pts with autoimmune diseases (2007) (0)
- Outcomes of early relapse following non-myeloablative allogeneic transplant for lymphoma (2010) (0)
- Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL). (2004) (0)
- CMV and HHV-6 after Chimeric Antigen Receptor (CAR)-T-Cell Immunotherapy for B-Cell Malignancies: A Prospective Study (2023) (0)
- 77 An NGS assay to identify HLA loss of heterozygosity for future CEA and MSLN logic-gated CAR-T solid tumor protocols designed for reduced on-target, off-tumor toxicity (2022) (0)
- Comorbidities, alcohol use disorder, and age predict outcomes following autologous hematopoietic cell transplantation for lymphoma (2016) (0)
- hematopoietic stem cell transplantation Graft-versus-host disease after nonmyeloablative versus conventional (2014) (0)
- A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2015) (0)
- Allogeneic Stem Cell Transplantation for Multiple Myeloma: Maxi, Mini, or in Between (2009) (0)
- SAFETY OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT IN ADULTS AFTER CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR‐MODIFIED T‐CELL (CAR‐T) THERAPY (2019) (0)
- Treatment Of Pediatric High-Risk Malignancies Using Non-Myeloablative (NM) Hematopoietic Cell Transplantation (HCT): A Multi-Institutional Experience (2010) (0)
- A Randomized Phase III Trial Investigating 2 Gy TBI Vs. Flu/2 Gy TBI Conditioning for HLA-Matched Related Donor Hematopoietic Cell Transplantation (HCT): Tempo of CD3 and NK Cell Engraftment Determines Relapse and Progression Free Survival in Patients with Hematologic (2012) (0)
- Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM). (2009) (0)
- Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma (2022) (0)
- A Phase II Trial of Myeloablative I-131-Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Transplantation for B-Cell Non-Hodgkin's Lymphoma (2012) (0)
- Immunotherapy for Non-Hodgkin’s Lymphoma (2001) (0)
- Early rituximab failure (ERF) in relapsed diffuse large b-cell lymphoma (DLBCL) and prediction of futility of autologous hematopoietic cell transplantation (AHCT). (2014) (0)
- Long-term Outcome of Patients with Multiple Myeloma after Autologous Hematopoietic Cell Transplantation and Nonmyeloablative Allografting Running title: Auto-Allotransplant in Multiple Myeloma (2008) (0)
- Rituximab and Interleukin 2 (IL2) as treatment for CD20+ non-Hodgkin's lymphoma (NHL) following autologous peripheral blood stem cell transplant (ASCT) (2004) (0)
- allogeneic hematopoietic cell transplantation: a study of 193 patients Hepatic injury after nonmyeloablative conditioning followed by (2013) (0)
- Efficacy and Safety of CAR T-Cell Therapy Using a Fully Human CD19-Targeted Binder in Adults with Relapsed/Refractory B-ALL (2022) (0)
- LOW-DOSE TBI-BASED NON-MYELOABLATIVE ALLOGRAFTING IN NEWLY DIAGNOSED MULTIPLE MYELOMA (2004) (0)
- Long-term outcomes with nonmyeloablative HLA-identical related HCT using tacrolimus and MMF for GVHD prophylaxis (2021) (0)
- Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Followed by Bortezomib Maintenance Therapy for High Risk Multiple Myeloma (2017) (0)
- Multifocal Not Single-Site FDG-PET Residual Disease Prior to Autologous Stem Cell Transplant for Hodgkin Lymphoma Associated with Adverse Outcome (2021) (0)
- Factors affecting immunologic recovery after nonmyeloablative conditioning (2006) (0)
- Novel CAR T Modules (Tmod) to Target HLA-Class I Loss in Lymphoma (2020) (0)
This paper list is powered by the following services:
Other Resources About David G. Maloney
What Schools Are Affiliated With David G. Maloney?
David G. Maloney is affiliated with the following schools:
